(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoint, showing a significant benefit in radiographic progression-free survival (rPFS) and a positive trend in overall … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged androgen receptor pathway inhibitors, cancer research, clinical trials, FDA approval, FDA regulatory review, metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Novartis, Novartis oncology, overall survival, Phase III PSMAddition, Pluvicto, progression-free survival, prostate cancer, prostate cancer treatment, PSMA-positive, radioligand therapy, treatment options
(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged adjuvant treatment, ASCO 2025, Black patients, Breast Cancer Treatment, CDK4/6 inhibitors, DDFS, disparities in healthcare, early breast cancer, EBC, endocrine therapy, HR+/HER2-, invasive disease-free survival, Kisqali®, metastatic breast cancer, Novartis, Phase III NATALEE, post-menopausal, pre-menopausal, recurrence-free survival, RFS, ribociclib, Risk Reduction, survival benefit
(IN BRIEF) The Vienna Stock Exchange has expanded its global market offering by allowing the trading of all stocks in the Swiss Market Index (SMI), which includes leading companies like Nestlé, Novartis, Roche, and UBS. This follows the Swiss Federal … Read the full press release
(IN BRIEF) Syngenta has acquired Novartis’ natural products and genetic strains assets to enhance its biologicals research capabilities and support the agricultural sector’s transition to sustainability. This acquisition complements the opening of a state-of-the-art biologicals production facility in South Carolina … Read the full press release
Posted in Agriculture, Chemicals, Industrial, Investment, Switzerland
Tagged AI, analytics, Basel, bio-insecticides, biocontrols, bioengineering, biologicals, biologicals production facility, Biomolecular Chemistry team, biostimulants, Camilla Corsi, crop protection, data science, downstream processing, fermentation, genetic strains, Ginkgo Bioworks, Intrinsyx Bio, Jonathan Brown, Latin America, Lavie Bio, Lithos Crop Protect, natural products, North America, Novartis, Novartis Natural Products, nutrient efficiency, nutrient use efficiency, Orangeburg, pheromone solutions, Provivi, Regenerative Agriculture, research and development, Seedcare, soil health, South Carolina, Sustainability Priorities, sustainable farming practices, Switzerland, Syngenta, TraitSeq, Valagro
(IN BRIEF) Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 trials for preventing stroke and systemic embolism in patients with atrial fibrillation. This acquisition … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, acquisition, Anthos Therapeutics, anticoagulation, atrial fibrillation, biopharmaceutical company, Blackstone Life Sciences, bleeding reduction, Boston, cancer-associated thrombosis, cardiovascular, cardiovascular therapeutic area, clinical-stage, David Soergel, Factor XI inhibition, Fast Track Designation, FDA, medical research, Novartis, partnership, Phase 3 trials, regulatory milestones, Shreeram Aradhye, stroke prevention, systemic embolism, therapeutic focus, thrombosis
(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged artificial intelligence, artnership, Circle of Scholars, doctoral students, Endress+Hauser Flowtec, ETH Zurich, ETH-HSG Manufacturing Alliance, Givaudan, Johnson & Johnson Innovative Medicine, Leila Schwery, Lindt & Sprüngli, manufacturing innovation, Nestlé, Novartis, Operational Excellence, Peter Hagmann, Roche, Schindler, Schneider Electric, SFS Group, SHL Medical, sustainable business practices, Swiss industry, Swiss Manufacturing Survey 2024, Takeda, talent development, University of St.Gallen, VAT Group
(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix achieved significantly higher major … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged 96-week results, asciminib, ASH Annual Meeting, chronic myeloid leukemia, CML care, discontinuation rate, imatinib, major molecular response, MMR, National Comprehensive Cancer Network, NCCN, newly diagnosed settings, Novartis, oncology, Ph+ CML-CP, Phase II ASC2ESCALATE trial, Phase III ASC4FIRST trial, Philadelphia chromosome-positive chronic myeloid leukemia, safety, Scemblix, Second-Line Treatment, severe adverse events, standard-of-care, TKIs, tolerability, tyrosine kinase inhibitors
(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant treatment for high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). The approval, based on the Phase III NATALEE trial, … Read the full press release
(IN BRIEF) MorphoSys AG has completed its voluntary delisting from the Frankfurt Stock Exchange and Nasdaq Global Market following its acquisition by Novartis. The delisting agreement, announced on June 20, 2024, and the subsequent delisting purchase offer by Novartis were … Read the full press release
Posted in Business, Economy, Environment, Financial, Germany, Government, Industrial, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acquisition, Frankfurt, MorphoSys, NASDAQ, Novartis, Novartis BidCo AG, partnership, sustainability, Switzerland
(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release
(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in treating relapsing multiple sclerosis (RMS) over a span of up to six years. The study, presented at the American Academy … Read the full press release
(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release
(IN BRIEF) Novartis, a leading pharmaceutical company, presented its ‘pure play’ innovative medicines strategy and focused Research and Development (R&D) pipeline at an event in London. The company’s CEO, Vas Narasimhan, emphasized Novartis’ transformation into an innovative medicines-focused firm, highlighting … Read the full press release
Posted in Business, Industrial, Management, Media, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 'Pure Play' Innovative Medicines Strategy, London Event, Novartis, R&D Pipeline, Vas Narasimhan
(IN BRIEF) Novartis has reported positive interim results from its Phase III ALIGN study involving atrasentan, an oral endothelin A receptor antagonist, for the treatment of IgA nephropathy (IgAN). The study demonstrated that atrasentan significantly reduced proteinuria (excess protein in … Read the full press release
(IN BRIEF) Sandoz Group AG, a Novartis spin-off, officially listed its shares at the SIX Swiss Exchange. With an opening share price of CHF 24.00, the market capitalization of Sandoz reached approximately CHF 10.3 billion. Sandoz’s issued share capital consists … Read the full press release
Posted in Business, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Switzerland
Tagged Financial, investment, Jos Dijsselhof, Novartis, partnership, Richard Saynor, Sandoz Group, shares, SIX Swiss Exchange
(IN BRIEF) Novartis has announced successful results from its Phase III NETTER-2 trial involving Lutathera, a treatment for neuroendocrine tumors (NETs). When used as a first-line treatment in combination with long-acting octreotide, Lutathera significantly improved progression-free survival in patients with … Read the full press release
(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz Group AG shares and ADRs scheduled to begin on October 4, 2023. This comes after receiving shareholder approval and key … Read the full press release
Posted in Business, Financial, Investment, Pharma & Biotech, Switzerland
Tagged ADRs, American Depositary Receipts, Novartis, Novartis ADR, OTCQX®, Sandoz, Sandoz Group AG, SDZ, shareholder, shares, SIX Exchange Regulation, SIX Swiss Exchange, SLI®, spin-off, SPI®, Swiss indices, Swiss Leader Index, Swiss Performance Index
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?